Cytori Therapeutics Inc (NASDAQ:CYTX) announced that the Company and Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S.
In a research report published Monday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Cytori Therapeutics Inc (NASDAQ:CYTX), with a $5.00 …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the publication of the results from an investigator-initiated Phase I trial using Cytori Cell Therapy in patients with insufficient …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that the use of Cytori Cell Therapy™ was approved for clinical use on June 24th, 2016 to treat knee …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced the publication in The Journal of Urology of a preclinical study applying Adipose-Derived Regenerative Cells (ADRCs) prepared using Cytori …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced Dr. Ramón Cugat MD, Ph.
Cytori Therapeutics Inc (NASDAQ:CYTX) announced completion of enrollment for its U.S.
Cytori Therapeutics Inc (NASDAQ:CYTX) announced it has commenced the subscription period for its previously announced rights offering of up to 6,896,551 units consisting of shares …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that on May 18, 2016, an update regarding the French SCLERADEC I and II clinical trials investigating the use …
Cytori Therapeutics Inc (NASDAQ:CYTX) announced that the European Commission has granted orphan drug status to a broad range of Cytori Cell Therapy® formulations when …
